Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.

Gómez-Miragaya J, Morán S, Calleja-Cervantes ME, Collado-Sole A, Paré L, Gómez A, Serra V, Dobrolecki LE, Lewis MT, Diaz-Lagares A, Eroles P, Prat A, Esteller M, González-Suárez E.

Mol Cancer Res. 2019 Oct;17(10):2063-2076. doi: 10.1158/1541-7786.MCR-19-0040. Epub 2019 Jul 18.

PMID:
31320385
2.

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.

Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.

Cancer Res. 2019 Aug 15;79(16):4258-4270. doi: 10.1158/0008-5472.CAN-18-3835. Epub 2019 Jun 18.

PMID:
31213465
3.

Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.

Ramirez AB, Bhat R, Sahay D, De Angelis C, Thangavel H, Hedayatpour S, Dobrolecki LE, Nardone A, Giuliano M, Nagi C, Rimawi M, Osborne CK, Lewis MT, Stilwell JL, Kaldjian EP, Schiff R, Trivedi MV.

BMC Cancer. 2019 Mar 12;19(1):220. doi: 10.1186/s12885-019-5382-1.

4.

C/EBPδ links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes.

Balamurugan K, Mendoza-Villanueva D, Sharan S, Summers GH, Dobrolecki LE, Lewis MT, Sterneck E.

Oncogene. 2019 May;38(20):3765-3780. doi: 10.1038/s41388-018-0516-5. Epub 2018 Sep 27.

5.

Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer.

Risom T, Langer EM, Chapman MP, Rantala J, Fields AJ, Boniface C, Alvarez MJ, Kendsersky ND, Pelz CR, Johnson-Camacho K, Dobrolecki LE, Chin K, Aswani AJ, Wang NJ, Califano A, Lewis MT, Tomlin CJ, Spellman PT, Adey A, Gray JW, Sears RC.

Nat Commun. 2018 Sep 19;9(1):3815. doi: 10.1038/s41467-018-05729-w.

6.

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF.

Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.

7.

Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer.

Zhao N, Cao J, Xu L, Tang Q, Dobrolecki LE, Lv X, Talukdar M, Lu Y, Wang X, Hu DZ, Shi Q, Xiang Y, Wang Y, Liu X, Bu W, Jiang Y, Li M, Gong Y, Sun Z, Ying H, Yuan B, Lin X, Feng XH, Hartig SM, Li F, Shen H, Chen Y, Han L, Zeng Q, Patterson JB, Kaipparettu BA, Putluri N, Sicheri F, Rosen JM, Lewis MT, Chen X.

J Clin Invest. 2018 Apr 2;128(4):1283-1299. doi: 10.1172/JCI95873. Epub 2018 Feb 26.

8.

Carbon nanotube capsules enhance the in vivo efficacy of cisplatin.

Guven A, Villares GJ, Hilsenbeck SG, Lewis A, Landua JD, Dobrolecki LE, Wilson LJ, Lewis MT.

Acta Biomater. 2017 Aug;58:466-478. doi: 10.1016/j.actbio.2017.04.035. Epub 2017 May 2.

9.

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.

Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, Phung TL, Mani SA, Stossi F, Sreekumar A, Mancini MA, Decker WK, Zong C, Lewis MT, Zhang XH.

Nature. 2017 Apr 13;544(7649):250-254. doi: 10.1038/nature21724. Epub 2017 Apr 3.

10.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

11.

Erratum: Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.

Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, Holdman XB, Herschkowitz JI, Pond A, Xie G, Kurley S, Nguyen T, Liao L, Dobrolecki LE, Pang L, Mo Q, Edwards DP, Huang S, Xin L, Xu J, Li Y, Lewis MT, Wang T, Westbrook TF, Rosen JM, Zhang XH.

Nat Cell Biol. 2016 Jun 28;18(7):822. doi: 10.1038/ncb3379. No abstract available.

PMID:
27350446
12.

Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.

Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, Holdman XB, Herschkowitz JI, Pond A, Xie G, Kurley S, Nguyen T, Liao L, Dobrolecki LE, Pang L, Mo Q, Edwards DP, Huang S, Xin L, Xu J, Li Y, Lewis MT, Wang T, Westbrook TF, Rosen JM, Zhang XH.

Nat Cell Biol. 2016 Jun;18(6):632-44. doi: 10.1038/ncb3355. Epub 2016 May 16. Erratum in: Nat Cell Biol. 2016 Jun 28;18(7):822.

13.

Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer.

Park JH, Vithayathil S, Kumar S, Sung PL, Dobrolecki LE, Putluri V, Bhat VB, Bhowmik SK, Gupta V, Arora K, Wu D, Tsouko E, Zhang Y, Maity S, Donti TR, Graham BH, Frigo DE, Coarfa C, Yotnda P, Putluri N, Sreekumar A, Lewis MT, Creighton CJ, Wong LC, Kaipparettu BA.

Cell Rep. 2016 Mar 8;14(9):2154-2165. doi: 10.1016/j.celrep.2016.02.004. Epub 2016 Feb 25.

14.

Human C6orf211 encodes Armt1, a protein carboxyl methyltransferase that targets PCNA and is linked to the DNA damage response.

Perry JJ, Ballard GD, Albert AE, Dobrolecki LE, Malkas LH, Hoelz DJ.

Cell Rep. 2015 Mar 3;10(8):1288-96. doi: 10.1016/j.celrep.2015.01.054. Epub 2015 Feb 26.

15.

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.

Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MV.

Breast Cancer Res. 2015 Jan 9;17:3. doi: 10.1186/s13058-014-0508-5.

16.

A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Smith SJ, Gu L, Phipps EA, Dobrolecki LE, Mabrey KS, Gulley P, Dillehay KL, Dong Z, Fields GB, Chen YR, Ann D, Hickey RJ, Malkas LH.

Mol Pharmacol. 2015 Feb;87(2):263-76. doi: 10.1124/mol.114.093211. Epub 2014 Dec 5.

17.

Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.

Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Adam A, Torres D, Zhang X, Dobrolecki LE, Wei W, Lewis MT, Dave B, Chang JC, Landis MD, Creighton CJ, Mancini MA, Tweardy DJ.

Oncogene. 2015 Mar 12;34(11):1341-53. doi: 10.1038/onc.2014.72. Epub 2014 Mar 31.

18.

Identification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy.

Zhang N, Scorsone K, Ge G, Kaffes CC, Dobrolecki LE, Mukherjee M, Lewis MT, Berg S, Stephan CC, Pati D.

J Biomol Screen. 2014 Jul;19(6):878-89. doi: 10.1177/1087057114520972. Epub 2014 Feb 13.

PMID:
24525869
19.

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.

Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT.

Cancer Res. 2013 Aug 1;73(15):4885-97. doi: 10.1158/0008-5472.CAN-12-4081. Epub 2013 Jun 4.

20.

Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.

Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC.

Clin Cancer Res. 2013 Mar 15;19(6):1512-24. doi: 10.1158/1078-0432.CCR-11-3326. Epub 2013 Jan 22.

21.

Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model.

Dave B, Landis MD, Tweardy DJ, Chang JC, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D, Lewis MT.

PLoS One. 2012;7(8):e30207. doi: 10.1371/journal.pone.0030207. Epub 2012 Aug 6. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/753d15c8-2321-4dc5-9b84-c47bd1bd1639.

22.

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.

Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC.

Breast Cancer Res Treat. 2010 Aug;123(1):189-96. doi: 10.1007/s10549-010-0983-z. Epub 2010 Jun 26.

PMID:
20582464
23.

A quantitative investigation of fucosylated serum glycoproteins with application to esophageal adenocarcinoma.

Mann B, Madera M, Klouckova I, Mechref Y, Dobrolecki LE, Hickey RJ, Hammoud ZT, Novotny MV.

Electrophoresis. 2010 Jun;31(11):1833-41. doi: 10.1002/elps.201000046.

24.

Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets.

Mechref Y, Hussein A, Bekesova S, Pungpapong V, Zhang M, Dobrolecki LE, Hickey RJ, Hammoud ZT, Novotny MV.

J Proteome Res. 2009 Jun;8(6):2656-66. doi: 10.1021/pr8008385.

25.

Elevated levels of hydroxylated phosphocholine lipids in the blood serum of breast cancer patients.

Hammad LA, Wu G, Saleh MM, Klouckova I, Dobrolecki LE, Hickey RJ, Schnaper L, Novotny MV, Mechref Y.

Rapid Commun Mass Spectrom. 2009 Mar;23(6):863-76. doi: 10.1002/rcm.3947.

PMID:
19224569
26.

Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.

Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV.

Clin Chem. 2008 Jul;54(7):1166-75. doi: 10.1373/clinchem.2007.087148. Epub 2008 May 16.

27.

Alterations in the serum glycome due to metastatic prostate cancer.

Kyselova Z, Mechref Y, Al Bataineh MM, Dobrolecki LE, Hickey RJ, Vinson J, Sweeney CJ, Novotny MV.

J Proteome Res. 2007 May;6(5):1822-32. Epub 2007 Apr 14.

28.

Comparison of computational algorithms for the classification of liver cancer using SELDI mass spectrometry: a case study.

Shen C, Breen TE, Dobrolecki LE, Schmidt CM, Sledge GW, Miller KD, Hickey RJ.

Cancer Inform. 2007 Dec 11;3:329-39.

29.

A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker.

Malkas LH, Herbert BS, Abdel-Aziz W, Dobrolecki LE, Liu Y, Agarwal B, Hoelz D, Badve S, Schnaper L, Arnold RJ, Mechref Y, Novotny MV, Loehrer P, Goulet RJ, Hickey RJ.

Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19472-7. Epub 2006 Dec 11.

30.

The discovery of labile methyl esters on proliferating cell nuclear antigen by MS/MS.

Hoelz DJ, Arnold RJ, Dobrolecki LE, Abdel-Aziz W, Loehrer AP, Novotny MV, Schnaper L, Hickey RJ, Malkas LH.

Proteomics. 2006 Sep;6(17):4808-16.

PMID:
16888766
31.

Neuroblastoma detection using serum proteomic profiling: a novel mining technique for cancer?

Sandoval JA, Dobrolecki LE, Huang J, Grosfeld JL, Hickey RJ, Malkas LH.

J Pediatr Surg. 2006 Apr;41(4):639-46; discussion 639-46.

PMID:
16567169

Supplemental Content

Loading ...
Support Center